Browse ASH2L

Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00622 SPRY domain
Function

Component of the Set1/Ash2 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3, but not if the neighboring 'Lys-9' residue is already methylated. As part of the MLL1/MLL complex it is involved in methylation and dimethylation at 'Lys-4' of histone H3. May function as a transcriptional regulator. May play a role in hematopoiesis.

> Gene Ontology
 
Biological Process GO:0006479 protein methylation
GO:0008213 protein alkylation
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0032259 methylation
GO:0034968 histone lysine methylation
GO:0043414 macromolecule methylation
GO:0043627 response to estrogen
GO:0051568 histone H3-K4 methylation
GO:1904837 beta-catenin-TCF complex assembly
Molecular Function GO:0003682 chromatin binding
GO:0008013 beta-catenin binding
GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016278 lysine N-methyltransferase activity
GO:0016279 protein-lysine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0018024 histone-lysine N-methyltransferase activity
GO:0042054 histone methyltransferase activity
GO:0042800 histone methyltransferase activity (H3-K4 specific)
GO:1990188 euchromatin binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0000791 euchromatin
GO:0005719 nuclear euchromatin
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0044454 nuclear chromosome part
GO:0044665 MLL1/2 complex
GO:0044666 MLL3/4 complex
GO:0048188 Set1C/COMPASS complex
GO:0071339 MLL1 complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3769402: Deactivation of the beta-catenin transactivating complex
R-HSA-1266738: Developmental Biology
R-HSA-201722: Formation of the beta-catenin
R-HSA-3214841: PKMTs methylate histone lysines
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ASH2L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ASH2L in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.83 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ASH2L in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1430.55
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4360.834
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.070.963
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0960.66
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0490.978
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1540.944
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0640.867
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0690.967
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.250.896
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0340.979
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5260.791
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2120.00941
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ASH2L in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ASH2L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ASH2L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ASH2L.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ASH2L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ASH2L expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ASH2L and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolASH2L
Nameash2 (absent, small, or homeotic)-like (Drosophila)
Aliases ASH2L2; Bre2; ASH2L1; ash2 (absent, small, or homeotic, Drosophila, homolog)-like; ASH21; ASH2-like protein; ......
Chromosomal Location8p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ASH2L collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.